Прогностическое значение экспрессии тимидинфосфорилазы, Bcl-2 и Ki-67 при раке почки Т1—2N0M0

1. Godley P.A. Renal cell carcinoma. Curr Opin Oncol 2001;13:199—203.

2. Eble J.N., Sauter G., Epsthan J.I., Sesterhehh I.A. Tumours of the urinary system and male genital organs. WHO Classification of tumours. 2002. p. 24—7.

3. Fuhrman S.A., Lasky L.C., Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6(7):655—63.

4. Imazano Y., Takebayashi Y., Nishiyama K. et al. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570—8.

5. Ishitsuka H., Miwa M., Ishikawa T. et al. Capecitabine: an orally available fluoropyrimidine with tumor selectivity. Proc Am Assoc Cancer Res 1995;36:2426.

6. Moghaddam A., Choudhuri R., Bicknell R. Tumour Angiogenesis. Oxford University Press; 1997. p. 287.

7. Suzuki K., Morita T., Hashimoto S. et al. Thymidine phosphorylase /plateletderived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urol Res 2001;29:7—12.

8. Mizutani Y., Wada H., Yoshida O. et al. The significance of thymidine phosphorylase /platelet-derived endothelial cell growth factor activity in renal cell carcinoma. Cancer 2003;98(4):730—6.

9. Morita T., Matsuzaki A., Tokue A. Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma. Oncology 2003;65(2):125—31.

10. Hirano Y., Takayama T., Kageyama S. et al. Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensivity to fluorouracil-related drugs. Urol Res 2002;30(2):112—5.

11. Wada S., Yoshimura R., Naganuma T. et al. Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma. BJU Int 2003;91:105—8.

12. Itoi T., Yamana K., Bilim V. et al. Impact of frequent Bcl-2 expression on better prognosis in renal cell carcinoma patients. Br J Cancer 2004;90:200—5.

13. Vasavada S.P., Novick A.C., Williams B.R. P53, bcl-2, and Bax expression in renal cell carcinoma. Urology 1998;51:1057—61.

14. Uchida T., Gao J.P., Wang G. et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002;59:615—20.

15. Rioux-Leclercq N., Turlin В., Bansard J. et al. Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma. Urology 2000;55(4):501—5.

16. Papadopoulos I., Weichert-Jacobsen К., Wacker H.H., Sprenger E. Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study. Eur Urol 1997;31(1):49—53.

17. Lam J.S., Shvarts O., Said J.W. et al. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer 2005;103(12):2517—25.

18. Bui M.H., Visapaa H., Seligson D. et al. Prognostic value of carbonic anhydrase IX and Ki-67 as predictors of survival for renal clear cell carcinoma. J Urol 2004;171(6):2461—6.